To assess the predictive value of baseline anti-PRMT5 antibody levels for skin fibrosis progression over a prospective 12-month period, we examined patients with SSc manifesting skin fibrosis progression, which was defined as an increase in mRSS ≥25% from baseline in the follow-up visit (12 months after baseline). Here, PRMT5 is linked to systemic sclerosis.